Onxeo: Quarterly Information as of September 30, 2014

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Onxeo: Quarterly Information as of September 30, 2014

Effective integration of both entities, BioAlliance Pharma and Topotarget, into newly named Onxeo Major advancements of company programs · Validive®: Positive preliminary top-results of the Phase II trial · Beleodaq®: Grant of U.S. marketing authorization and first sales · Livatag®: Active recruitment in the ReLive trial with nearly 35% of planned patients already randomized Significantly improved cash position PARIS & COPENHAGEN, Denmark--(BUSINESS WIRE (http://www.businesswire.com/))-- Regulatory News: Onxeo SA (Paris:ONXEO) (NASDAQ OMX:ONXEO) (Euronext Paris, NASDAQ OMX Copenhagen - ONXEO), an innovative biopharmaceutical company specializing in the development of orphan oncology drugs, today publishes the major key milestones achieved during the third quarter of 2014 and the last few weeks. Since August 1st, 2014, the newly named company Onxeo resulting from the merger of Topotarget and BioAlliance Pharma is fully operating with teams in France and Denmark. Onxeo has achieved major milestones in the development of its key programs in orphan oncology: Validive® (clonidine Lauriad®) · Positive preliminary top-line results of the international large Phase II trial comparing the efficacy and safety of Validive® versus placebo in the prevention of oral severe mucositis in Head and Neck cancer patients. Experts have confirmed that these data were supportive to further pursue Validive® development plan. Validive® peak sales potential is estimated between €200 and €400 million. Beleodaq® (belinostat) · Grant of US conditional marketing authorization of Beleodaq® for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This approval has triggered a $25 million milestone payment from American partner Spectrum Pharmaceuticals, to be received by year-end by the company. The commercialization of Beleodaq® by the Spectrum Pharmaceuticals’ oncology sales team started in late July 2014 and the first promising sales have been registered over Q3. Livatag® (doxorubicin Transdrug™) · Active recruitment in the phase III trial ReLive in primary liver cancer, with nearly 35% of planned patients already randomized, in line with the study planning. Other programs · Launch of Sitavig® , approved in the US for the treatment of labial herpes by the US based licensee Innocutis towards to dermatologists and top tier general practitioners,first promising sales reported after a few weeks of promotion. · Decision to stop Amep® biotherapy development to reinforce focus onOnxeo’s advanced strategic programs. Financials The consolidated turnover for the third quarter 2014 has increased significantly compared to same period in 2013: Consolidated revenues –       Q3 2014       Q3 2013 IFRS – in thousands Euros Non-recurring revenues       19,911       133 from out-licensing agreements Recurring revenues from       622       113 out-licensing agreements Other revenues       55       0 TOTAL       20,588       246 · Non-recurring revenues have surged as a result of the $25 million milestone from Spectrum Pharmaceuticals linked to Beleodaq® market authorization and the $1.9 million upfront payment from Innocutis due at delivery of the first commercial batch of Sitavig®. · Recurring revenues reflect royalties received, including royalties on Beleodaq® and Sitavig® sales on the US market. · As a result of the merger and with the €10 million loan from our major shareholder Financière de la Montagne, put in place in July, the cash position has been significantly improved and reaches €20.7 million as of September 30th, 2014. During Q4, this position will be further strengthened with the $25 million milestone payment from Spectrum Pharmaceuticals and the €1.25 million second milestone of BPIfrance grant dedicated to the Livatag® development as a part of the NICE (Nano Innovation for Cancer) consortium. Governance Now that the merger process is fully completed, Mr. Per Samuelsson and Dr. Bo Jesper Hansen are leaving the Board as of November 7th. Dr Hansen has brought to the Board's attention a newly emerged potential conflict of interest, which requires his stepping down in line with good governance practices; Mr. Per Samuelsson has asked to be relieved from the Board to allow more time to other assignments. In parallel, the company board of Directors will evolve to add new expertise, especially to reinforce its scientific skills in line with its ambition to become a global leader in Orphan Oncology. “Merger and integration have been successfully achieved, and we at HealthCap have full confidence that Onxeo has the assets and the teams to achieve its ambition and create strong value for its shareholders”, declares Per Samuelsson. “I would like to thank Bo Jesper and Per for their support in the merger process as well as during the effective implementation”, declares Mr. Patrick Langlois, chairman of the Board. Perspectives and clinical challenges Validive®: Based on the positive phase II results, the company will initiate the preparation of a phase III trial to evaluate Validive® efficacy. Thanks to its fast track status in the US, discussions with FDA will be eased and the company plans to submit this new study in the course of 2015. Beleodaq®: Following the conditional marketing authorization in 2nd line PTCL, a phase III trial will be initiated together with Spectrum Pharmaceuticals to confirm Beleodaq® efficacy and safety in PTCL 1st line, both in the US and Europe. Other indications are also reviewed by the company and Spectrum Pharmaceuticals to further develop Beleodaq®’s potential. Livatag®: As planned, the fifth DSMB will be held Q4 2014, to evaluate the tolerance of Livatag® in nearly 35% of planned patients randomized. As of now, DMSB has each time unanimously recommended continuing the study without modification, based on positive assessment of Livatag® safety data. “The first months of Onxeo are marked by very successful and crucial achievements on key products. Beleodaq® has been registered and launched on the U.S. market, Validive® phase II has shown positive results allowing its passage into phase III. Next critical steps in the coming months will be to design the most effective development plans for these two products”. declares Judith Greciet, CEO of Onxeo “With a reinforced cash position, a strengthen team thanks to the merger with Topotarget and enlarged promising pipeline, Onxeo has reinforced during the course of the past months its postion to become a major player in Orphan oncology ”, she continues. About Onxeo Onxeo has the vision to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, through developing innovative therapeutic alternatives to “make the difference”. The Onxeo teams are determined to develop innovative medicines to provide patients with hope and significantly improve their lives. Key products at advanced development stage are: Livatag® (Doxorubicin Transdrug™): Phase III in hepatocellular carcinoma Validive® (Clonidine Lauriad®): Phase II in severe oral mucositis: Positive preliminary top-line results Beleodaq® (belinostat): registered in the US in peripheral T-cell lymphoma For more information, visit the website www.onxeo.com (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3 A %2F%2Fwww.onxeo.com&esheet=50978759&newsitemid=0&lan=en -US&anchor=www.onxeo.com&index=1&md5=4139f0caf1956202684b05be6ef577dd) Disclaimer This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward -looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2013 Reference Document filed with the AMF on April 7, 2014, which is available on the AMF website (http://www.amf -france.org (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww . amf-france.org&esheet=50978759&newsitemid=0&lan=en -US&anchor=http%3A%2F%2Fwww.amf -france.org&index=2&md5=fb8474b8d939bfdc1f3a104c3c296fc2)) or on the company’s website (www.onxeo.com (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2F w ww.onxeo.com&esheet=50978759&newsitemid=0&lan=en -US&anchor=www.onxeo.com&index=3&md5=f034103311afce83644ca0a601675ed2)). Judith Greciet, CEO j.greciet@onxeo.com +33 1 45 58 76 00 or Nicolas Fellmann, CFO n.fellmann@onxeo.com +33 1 45 58 76 00 or Caroline Carmagnol / Sophie Colin – Alize RP caroline@alizerp.com / scolin@alizerp.com +33 6 64 18 99 59 / +33 1 44 54 36 62

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Luxury's €1.5 Trillion Market Has Moved to Memories

Updated Category News Views 93

A €1.5 trillion market that cannot grow much is still a market worth fighting over, but luxury's old playbook is looking awfully tired. Bain's 2026 view is for global luxury spending to land somewhere between flat and up 2% at constant exchange rates versus 2025. That is stability, not a victory parade. Yet the total market remains 16% to 22% above 2019 levels, and the...

Continue Reading
Exiger's CEO Honored for Military Support Excellence

Updated Category News Views 141

Recognizing Civilian and Military Leadership When you hear "recognition in the military sector," it isn't just a pat on the back. It's a whole parade of brass hats and high-flyers giving their nods. So, November 10th wasn't just any regular day—Brandon Daniels, CEO of Exiger, gets a shiny, prestigious Five-Star Award for his "extraordinary support" of our military...

Continue Reading
Envision and Tai Tam Put 45 MW Wind Bet to Work in Vietnam

Updated Category News Views 116

A wind site averaging 6.5 meters per second can look unremarkable on a map, yet that is precisely where equipment choices start separating serious developers from brochure merchants. Envision Energy and Vietnam's Tai Tam Group are taking that test on with the 45 MW Phuoc Dan wind project in Khanh Hoa Province. The arrangement follows five years of cooperation, but the...

Continue Reading
Cadence Marks $2.7 Million for St. Jude Family Care

Updated Category News Views 21

Small Wheels, Serious Purpose Tiny tricycles, flour-dusted bake-sale tables, and family pledges have pushed Cadence Education’s St. Jude partnership to $2.7 million since 2018. That number is not a flashy balance-sheet item, nor should anybody try to dress it up as one. It is the accumulated result of school communities showing up year after year, and in a sector built...

Continue Reading
Unishippers Climbs 18 Slots on 32.4% Sales Growth Run

Updated Category News Views 184

Thirty new franchise units can move the needle fast Unishippers did not inch its way up the Franchise Times Top 400; it put up a number that deserves a hard look. Sales rose 32.4% in 2025, the company added 30 franchise units, and the result was an 18-place jump to No. 81 on the 2026 ranking. In the shipping category, it was named the sales-growth leader. For a business...

Continue Reading
TGHL Eyes U.S. Battery Shift Through EnChem Merger

Updated Category News Views 112

A Policy Squeeze Is Rewriting the Battery Map Battery supply chains are getting shoved through a narrower gate, and that is exactly why this proposed deal deserves a hard look. The GrowHub Limited wants to acquire EnChem America, a Georgia-based lithium-ion battery electrolyte producer, and the timing is plainly built around Washington's push to reduce reliance on...

Continue Reading
COPD Support Program Targets a Costly Care Gap Today

Updated Category News Views 107

Breathing trouble gets shrugged off far too easily, and that casual mistake has consequences. World COPD Day puts chronic obstructive pulmonary disease back in view, with the American Lung Association emphasizing a free Lung Health Navigator program for people living with COPD, their caregivers and families. This is not flashy medicine or a miracle-cure pitch. It is...

Continue Reading
Inhibrx Ewing Data Gives Ozekibart a Real Clinical Signal

Updated Category News Views 165

Numbers this lopsided in relapsed Ewing sarcoma make me sit up straight, even after years of watching oncology releases try to turn every blip into a brass band. Inhibrx has reported updated Phase 1/2 data for ozekibart, paired with irinotecan and temozolomide, that look genuinely notable in a disease where patients have very few good cards left to play. That matters...

Continue Reading
Italian Wine Faces U.S. Slump and New Market Openings

Updated Category News Views 75

American demand has put a cork in the easy story, and Italian wine producers cannot pretend otherwise. In the first nine months of 2026, U.S. imports of Italian wine dropped 18.4% by value. That is painful because the United States remains Italy's largest destination market by value, not some side shelf that can be ignored until conditions improve. Still, the broader U.S....

Continue Reading
Halff Elevates People and Delivery Leadership Team

Updated Category News Views 90

Infrastructure outfits rarely make much noise when they reshuffle leadership, but Halff’s Nov. 18 announcement deserves a closer look than the usual executive-title confetti. The employee-owned consulting firm has put Greg Carpenter in the chief people officer seat and named Leigh Hollis chief delivery officer. One role is aimed squarely at the human machinery; the...

Continue Reading

Top 5 Most Recently Viewed Articles

Venus Concept Strengthens Financial Position with Debt Exchange

Updated Category News Views 173

Venus Concept Optimizes Capital Structure through Debt Exchange Venus Concept Inc. is making waves in the medical aesthetic technology industry with its recent strategic financial decision. The company, known for its innovative solutions, has successfully exchanged $11 million worth of subordinated convertible notes for 379,311 shares of Series Y preferred stock. This...

Continue Reading
Understanding the Recent Decline of Gentex Corporation Stock

Updated Category News Views 284

Why Is Gentex Corporation Stock Down? Gentex Corporation (NASDAQ:GNTX) shares have recently faced a decline after revealing third-quarter earnings that fell short of expectations. The drop can be largely attributed to lower-than-expected earnings per share (EPS) and sales figures. Quarterly Earnings Performance For the third quarter, Gentex reported adjusted earnings of...

Continue Reading
Elliott Pressures Northern Star: Board Shake-Up Needed

Updated Category News Views 59

Reckoning Time for Northern Star Resources Well, it's about time someone rattled the cage at Northern Star. Elliott Management, never one to sit on its laurels, is clapping back at the board with a stern letter, raising eyebrows and hopes for a shake-up. They're putting their 5.6% stake to work, backing their talk with a lineup of heavyweight board candidates. The message...

Continue Reading
CBD's Role in Supporting World Cup Soccer Players

Updated Category News Views 60

World Cup Sparks Focus on Player Recovery An event like the FIFA World Cup doesn't just put its spotlight on dazzling goals and nail-biting penalty shootouts; it throws the grueling demands placed on players into sharp relief. With fixtures spread across sprawling global schedules, these athletes barely get time to breathe between matches. Rest Rules Let Players Recharge...

Continue Reading
Middlefield Canadian Income PCC: Major Holdings Announcement

Updated Category News Views 185

Overview of Middlefield Canadian Income PCC Holdings Middlefield Canadian Income PCC is actively engaged in managing major holdings and ensuring transparency in its share structure. The company recently issued a comprehensive notification, detailing the current shareholding status and changes in voting rights, importantly reflecting the interests of its shareholders....

Continue Reading